EADV 2024 Highlights Podcast Presented ByDr Rachel Giles, Medicom ConferenceEADV 2024 9 October 2024 23:36
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema Presented ByProf. Ana Giménez-Arnau, Pompeu Fabra University, Spain TrialPhase 3, DELTA FORCE ConferenceEADV 2024 TypeNews article 2 October 2024 12:13
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa Presented ByDr Kim Papp, Probity Medical Research, Canada TrialPhase 3 ConferenceEADV 2024 TypeNews article 1 October 2024 11:57
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema Presented ByProf. Ana Giménez-Arnau, Pompeu Fabra University, Spain TrialPhase 3, DELTA FORCE ConferenceEADV 2024 TypeNews article 2 October 2024 12:13
Second-generation selective PDE-4 inhibitor shows promise in AD Presented ByProf. Eric Simpson, Oregon Health and Science University, USA TrialPhase 2, ADESOS ConferenceEADV 2024 TypeNews article 2 October 2024 12:08
HS: Bimekizumab shows sustained 2-year efficacy Presented ByProf. Christos Zouboulis, Dessau Medical Centre, Germany TrialBE HEARD EXT ConferenceEADV 2024 TypeNews article 2 October 2024 12:06
JAK1 inhibitor shows promising long-term efficacy in PN Presented ByDr Shawn Kwatra, Johns Hopkins University School of Medicine, USA TrialPhase 2 ConferenceEADV 2024 TypeNews article 2 October 2024 12:04
Deuruxolitinib significantly improves hair satisfaction in alopecia areata Presented ByDr Paradi Mirmirani, Kaiser Permanente Vallejo Medical Center, USA TrialTHRIVE-AA1; THRIVE-AA2 ConferenceEADV 2024 TypeNews article 2 October 2024 12:02
Familial hidradenitis suppurativa associated with higher risk for metabolic disease Presented ByDr Suzan Al-Gburi, University Hospital Cologne, Germany ConferenceEADV 2024 TypeNews article 2 October 2024 11:58
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa Presented ByDr Kim Papp, Probity Medical Research, Canada TrialPhase 3 ConferenceEADV 2024 TypeNews article 1 October 2024 11:57
Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis Presented ByProf. Adam Reich, Medical College of Rzeszow, Poland TrialPhase 3, GEMINI-1; GEMINI-2 ConferenceEADV 2024 TypeNews article 1 October 2024 11:55
Prurigo nodularis: long-term treatment reduces relapse events Presented ByProf. Franz Legat, Medical University Graz, Austria TrialPhase 3 ConferenceEADV 2024 TypeNews article 1 October 2024 11:53
Atopic dermatitis early in life imposes a lifelong psychosocial burden Presented ByProf. Jonathan Silverberg, The George Washington University School of Medicine, USA ConferenceEADV 2024 TypeNews article 1 October 2024 11:51
PsoBest registry: Biologics have become the first choice in moderate-to-severe psoriasis Presented ByProf. Matthias Augustin, Univeristy of Hamburg, Germany ConferenceEADV 2024 TypeNews article 1 October 2024 11:50
Topical pan-JAK inhibitor mitigates inflammatory biomarkers in frontal fibrosing alopecia Presented ByProf. Maryanne Senna, Harvard Medical School, MA, USA TrialPhase 2 ConferenceEADV 2024 TypeNews article 1 October 2024 11:40
Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib Presented ByProf. April Armstrong, University of California Los Angeles, USA TrialPhase 3, LIBERTY-AD-HAFT; DELTA ConferenceEADV 2024 TypeNews article 30 September 2024 11:32
IL-13 inhibitor shows safety and efficacy in AD over 3 years Presented ByProf. Diamant Thaçi , University of Lübeck, Germany TrialADjoin; ADvocate ConferenceEADV 2024 TypeNews article 30 September 2024 11:29
Semaglutide: also beneficial for patients with HS? Presented ByDr Daniel Lyons, St Vincent’s University Hospital, Ireland ConferenceEADV 2024 TypeNews article 30 September 2024 11:24
Advanced BCC: histological subtype and time to complete response may predict tumour recurrence Presented ByDr Maria Mannino, Catholic University of the Sacred Heart, Italy ConferenceEADV 2024 TypeNews article 30 September 2024 11:22
New targets identified for chronic wound healing Presented ByDr Marta Bertolini, QIMA Monasterium GmbH, Germany ConferenceEADV 2024 TypeNews article 30 September 2024 11:19